Salarius Pharmaceuticals (DCOY) Q2 2022 Earnings Call Summary

1Key Financial Results and Metrics:

Net Loss: $4.7 million ($0.09 per share) for Q2 2022, compared to $3.1 million ($0.07 per share) in Q2 2021.

Year-to-Date Net Loss: $10.8 million ($0.22 per share) for the first half of 2022, up from $4.9 million ($0.13 per share) in the same period of 2021.

Research and Development Expenses: Increased to $2.9 million in Q2 2022 from $2.1 million in Q2 2021, primarily due to spending on targeted protein degradation technology.

General and Administrative Expenses: Rose to $1.8 million from $1.6 million year-over-year, attributed to higher personnel costs.

Cash Position: As of June 30, 2022, cash and cash equivalents totaled $22.6 million, down from $29.2 million at the end of 2021, expected to fund operations into 2023.

2Strategic Updates and Business Highlights:

Continued progress in clinical trials for seclidemstat, a reversible LSD1 protein inhibitor, with enrollment in a Phase 1/2 study for Ewing’s and FET-rearranged sarcomas.

Collaboration with Volition Rx for rapid epigenetic profiling to assess drug activity in patients, with data collection expected by year-end.

Development of SP-3164, a targeted protein degrader, is on track for an IND submission in the first half of 2023, following successful pre-IND meetings with the FDA.

Attendance at the 2022 BIO International Conference to engage with pharmaceutical companies and gather feedback on clinical data requirements.

3Forward Guidance and Outlook:

Anticipation of interim clinical data from the seclidemstat trials later in 2022, with potential positive impacts on treatment options for patients with high unmet needs.

Plans to provide updates on preclinical data for SP-3164 later this year, with clinical trials expected to commence soon after IND submission.

Future conference calls will be event-driven, focusing on significant clinical or preclinical data releases rather than adhering to a fixed schedule.

4Bad News, Challenges, or Points of Concern:

Increased net loss and operational expenses compared to the previous year, with no grant revenue recorded in 2022, contrasting with $1.8 million in the first half of 2021.

The absence of grant revenue may impact financial stability and resource allocation for ongoing and future projects.

The competitive landscape for protein degradation therapies is intensifying, with large pharmaceutical companies actively pursuing partnerships in this area.

5Notable Q&A Insights:

Enrollment Status: Enrollment for the seclidemstat trial is progressing well, with the addition of several prestigious clinical sites. Specific enrollment numbers were not disclosed.

Data Dissemination: Interim data will likely be released via press release or at conferences, depending on the readiness and ethical considerations surrounding the information.

IND Enabling Studies: SP-3164's IND enabling studies are underway, with a focus on mechanism of action and proof of concept data expected to be presented at an upcoming conference. Overall, Salarius Pharmaceuticals is positioned for a potentially impactful second half of 2022, with ongoing clinical trials and strategic partnerships, despite facing financial challenges and a competitive market landscape.